Logo image of GOVX

GEOVAX LABS INC (GOVX) Stock Fundamental Analysis

USA - NASDAQ:GOVX - US3736786068 - Common Stock

0.5525 USD
-0.01 (-1.71%)
Last: 10/17/2025, 8:17:09 PM
0.59 USD
+0.04 (+6.79%)
After Hours: 10/17/2025, 8:17:09 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to GOVX. GOVX was compared to 536 industry peers in the Biotechnology industry. GOVX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GOVX is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GOVX had negative earnings in the past year.
GOVX had a negative operating cash flow in the past year.
In the past 5 years GOVX always reported negative net income.
GOVX had a negative operating cash flow in each of the past 5 years.
GOVX Yearly Net Income VS EBIT VS OCF VS FCFGOVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

With a Return On Assets value of -463.62%, GOVX is not doing good in the industry: 96.08% of the companies in the same industry are doing better.
The Return On Equity of GOVX (-879.26%) is worse than 80.97% of its industry peers.
Industry RankSector Rank
ROA -463.62%
ROE -879.26%
ROIC N/A
ROA(3y)-210.29%
ROA(5y)-163.35%
ROE(3y)-332.78%
ROE(5y)-290.99%
ROIC(3y)N/A
ROIC(5y)N/A
GOVX Yearly ROA, ROE, ROICGOVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

GOVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GOVX Yearly Profit, Operating, Gross MarginsGOVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

5

2. Health

2.1 Basic Checks

GOVX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GOVX has been increased compared to 1 year ago.
Compared to 5 years ago, GOVX has more shares outstanding
There is no outstanding debt for GOVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GOVX Yearly Shares OutstandingGOVX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
GOVX Yearly Total Debt VS Total AssetsGOVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

GOVX has an Altman-Z score of -46.97. This is a bad value and indicates that GOVX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -46.97, GOVX is doing worse than 92.91% of the companies in the same industry.
GOVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -46.97
ROIC/WACCN/A
WACC9.35%
GOVX Yearly LT Debt VS Equity VS FCFGOVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 2.03 indicates that GOVX has no problem at all paying its short term obligations.
The Current ratio of GOVX (2.03) is worse than 74.25% of its industry peers.
A Quick Ratio of 2.03 indicates that GOVX has no problem at all paying its short term obligations.
The Quick ratio of GOVX (2.03) is worse than 72.76% of its industry peers.
Industry RankSector Rank
Current Ratio 2.03
Quick Ratio 2.03
GOVX Yearly Current Assets VS Current LiabilitesGOVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 91.21% over the past year.
Looking at the last year, GOVX shows a very strong growth in Revenue. The Revenue has grown by 1942.93%.
GOVX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 27.45% yearly.
EPS 1Y (TTM)91.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.41%
Revenue 1Y (TTM)1942.93%
Revenue growth 3Y117.28%
Revenue growth 5Y27.45%
Sales Q2Q%183.06%

3.2 Future

The Earnings Per Share is expected to grow by 32.77% on average over the next years. This is a very strong growth
Based on estimates for the next years, GOVX will show a very strong growth in Revenue. The Revenue will grow by 278.07% on average per year.
EPS Next Y76.85%
EPS Next 2Y33.03%
EPS Next 3Y32.77%
EPS Next 5YN/A
Revenue Next Year-56.94%
Revenue Next 2Y-41.42%
Revenue Next 3Y278.07%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
GOVX Yearly Revenue VS EstimatesGOVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2027 100M 200M 300M
GOVX Yearly EPS VS EstimatesGOVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 -5 -10 -15 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GOVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GOVX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GOVX Price Earnings VS Forward Price EarningsGOVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GOVX Per share dataGOVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as GOVX's earnings are expected to grow with 32.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.03%
EPS Next 3Y32.77%

More info and screens

0

5. Dividend

5.1 Amount

GOVX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GEOVAX LABS INC

NASDAQ:GOVX (10/17/2025, 8:17:09 PM)

After market: 0.59 +0.04 (+6.79%)

0.5525

-0.01 (-1.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-28 2025-07-28/amc
Earnings (Next)11-10 2025-11-10
Inst Owners2.18%
Inst Owner Change0%
Ins Owners0.49%
Ins Owner Change0.64%
Market Cap16.41M
Analysts81.82
Price Target10.1 (1728.05%)
Short Float %15.94%
Short Ratio4.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.25%
Min EPS beat(2)4.68%
Max EPS beat(2)33.82%
EPS beat(4)4
Avg EPS beat(4)34.96%
Min EPS beat(4)4.68%
Max EPS beat(4)61.7%
EPS beat(8)6
Avg EPS beat(8)-21.58%
EPS beat(12)8
Avg EPS beat(12)-17.72%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)77.25%
Min Revenue beat(2)26.69%
Max Revenue beat(2)127.81%
Revenue beat(4)3
Avg Revenue beat(4)71.93%
Min Revenue beat(4)-64.4%
Max Revenue beat(4)197.61%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.48%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.19%
EPS NY rev (1m)10.02%
EPS NY rev (3m)21.74%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)38.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.28
P/FCF N/A
P/OCF N/A
P/B 4.97
P/tB 4.97
EV/EBITDA N/A
EPS(TTM)-2.01
EYN/A
EPS(NY)-1.31
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0.24
BVpS0.11
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -463.62%
ROE -879.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-210.29%
ROA(5y)-163.35%
ROE(3y)-332.78%
ROE(5y)-290.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover1.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.29%
Cap/Sales 0.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.03
Quick Ratio 2.03
Altman-Z -46.97
F-Score5
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)108.76%
Cap/Depr(5y)249.22%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)91.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.41%
EPS Next Y76.85%
EPS Next 2Y33.03%
EPS Next 3Y32.77%
EPS Next 5YN/A
Revenue 1Y (TTM)1942.93%
Revenue growth 3Y117.28%
Revenue growth 5Y27.45%
Sales Q2Q%183.06%
Revenue Next Year-56.94%
Revenue Next 2Y-41.42%
Revenue Next 3Y278.07%
Revenue Next 5YN/A
EBIT growth 1Y8.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-83000.3%
EBIT Next 3Y649.13%
EBIT Next 5YN/A
FCF growth 1Y-32.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.36%
OCF growth 3YN/A
OCF growth 5YN/A